Simulations Plus, Inc.

Please join us in welcoming Dr. Deanna Mudie to Simulations Plus as Senior Principal Scientist of Physiologically Based Pharmacokinetics (PBPK) Solutions! Deanna has more than 20 years of experience in the pharmaceutical industry. She most recently served as a technical program lead in Research and Development at Lonza Small Molecules. She brings a wealth of experience and insight to this role, and we are excited how she and the rest of the PBPK team will be able to support you in your work. https://lnkd.in/gtkqya38

Are you leveraging the full potential of your technology investments? We’re hosting a free two-day event, MIDD+ San Francisco, where you can learn how industry peers across disciplines are getting deeper insight and actionable data using modeling and simulation (M&S) software. You will hear scientific presentations and real-life case studies from industry leaders, get hands-on learning from our software experts, and the opportunity to network and connect with other scientists in your region. https://lnkd.in/gyR5p9eM

Can't wait until May 15th to get your hands on GPX? Check out this teaser video for a sneak peek of the new features and upgraded design. https://lnkd.in/g-7c9EwX

What is the importance of model-informed drug-development (MIDD)?  John DiBella, President of PBPK and Cheminformatics Solutions, offers three reasons you should incorporate MIDD approaches in your drug development program.  https://lnkd.in/gj3246Zy 

Do you have questions about the new MonolixSuite™ 2024? Join us for our office hours! Register and fill out the survey in the first module to submit your questions. Then, we’ll answer them during the live sessions. For those that can’t attend live, a recording will be available. Register today to save your spot. https://lnkd.in/gjuW_nm5

Are you at the ARVO Annual Meeting? Make your way over to poster board #B0369 to learn how the utility of an ocular PBPK model was used to predict human exposure following the administration of ophthalmic ointment. https://lnkd.in/gsPuQE7 Check out our resource center for a downloadable version after the conference. https://lnkd.in/gRrfUme

You’re ready to get started with GPX—but is your IT team? In our upcoming webinar, attendees will get practical tips and best practices for the software installation process from our IT, Learning Services, and Software Licensing teams. https://lnkd.in/gmXywf2T

Please join us in welcoming Dr. Alfredo García Arieta to Simulations Plus as our new Associate Vice President, Regulatory Strategies. Dr. García Arieta spent more than 25 years serving the Spanish Agency for Medicines and Health Products, helping to provide guidance for and ensure the efficacy and safety of drug products making their way to market. Through his time at the EMA and engagement in various initiatives, including serving as an external consultant for Bioequivalence in the Prequalification Team (PQT/MED) of the World Health Organization, Dr. García-Arieta has acquired a thorough comprehension of both drug product development and regulatory decision-making processes. As part of the Regulatory Strategies team at Simulations Plus, he will utilize this expertise to support our clients in charting a course for drug product approval supported by modeling and simulation, while identifying alternative routes to expedite drug product development. Learn more about the support Dr. García-Arieta and our regulatory strategies team can provide. https://lnkd.in/g-7ACNda

Thanks to our MIDD+ speakers, Vladimir Chupakhin, Ka Ning Yip, Ridwan Islam, M. Pharm., Ph.D., Kishore Pasikanti, Viera Lukacova, Daniel J. O'Connor, Sr., Steven Chang, Weirong Wang, Xinyuan (Susie) Zhang, Birgit Schoeberl, for sharing insights of model-informed drug development (MIDD). We're looking forward to seeing you all back tomorrow for day 2!   Register for our News & Events emails to hear about future conferences, trainings, and events. https://lnkd.in/grWuNb-5

Are you attending the 2024 Drug Induced Liver Injury Conference in Washington, D.C.? Join Kyunghee Yang for her presentation on how QST modeling was used to evaluate hepatic safety of five calcitonin gene-related peptide (CGRP) inhibitors and fezolinetant to inform decision making. In addition, she will discuss the application of QST modeling and mechanistic toxicity data from Liver Acinus MicroPhysiology System (LAMPS) to investigate biologics-mediated hepatotoxicity will be presented using tocilizumab as a case study. https://lnkd.in/gjiCZCXG